- Stocks
- Pharma & Healthcare
- Aarey Drugs & Pharmaceuticals
Aarey Drugs & Pharmaceuticals share price
NSE: AAREYDRUGSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Aarey Drugs & Pharmaceuticals at a glance
Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) closed at ₹111.75 on 22 Oct 2026, down 0.84% on the day. With a market capitalisation of ₹317 Cr, it ranks 2018th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 80.4× trailing earnings, against a return on equity of 2.9% in FY25. Over the past year the share price has risen 31.2%. Its 52-week range is ₹50.31 (30 Mar 2026) to ₹114.80 (19 Oct 2026); the last close is 2.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹189 Cr (+75.3% year on year) and net profit ₹2 Cr (+231.9%), on a standalone basis. Promoters held 37.71% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹317 CrRank 2018 on NSE
- P/E (trailing)
- 80.4×
- Price to book
- 0.69×FY25
- EPS (TTM)
- ₹1.59to Q4 FY26
- ROE
- 2.9%FY25
- ROCE
- 7.6%FY25
- Debt to equity
- 0.25FY25
- Net profit margin
- 0.8%FY25
- Book value / share
- ₹48.67FY25
- 52-week high
- ₹114.8019 Oct 2026
- 52-week low
- ₹50.3130 Mar 2026
- 1-year return
- +31.2%
- RSI (14-day)
- 64.2
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.84% | +4.5% | +11.2% | +47.1% | +31.2% |
Aarey Drugs & Pharmaceuticals quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹127 Cr | ₹105 Cr | ₹134 Cr | ₹108 Cr | ₹102 Cr | ₹84 Cr | ₹96 Cr | ₹189 Cr |
| Revenue YoY | +149.0% | +81.8% | +74.9% | −48.6% | −19.5% | −20.0% | −27.9% | +75.3% |
| Net profit | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Net profit YoY | +72.2% | +105.1% | −29.4% | −78.1% | +10.5% | −36.3% | −20.8% | +231.9% |
| Net margin | 1.0% | 1.5% | 0.5% | 0.4% | 1.3% | 1.2% | 0.6% | 0.8% |
| EPS | ₹0.44 | ₹0.57 | ₹0.26 | ₹0.02 | ₹0.48 | ₹0.36 | ₹0.20 | ₹0.55 |
Aarey Drugs & Pharmaceuticals financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹300 Cr | ₹348 Cr | ₹493 Cr | ₹419 Cr | ₹396 Cr | ₹474 Cr |
| Operating profit | ₹7 Cr | ₹8 Cr | ₹10 Cr | ₹6 Cr | ₹5 Cr | ₹6 Cr |
| Net profit | ₹6 Cr | ₹7 Cr | ₹7 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr |
| EPS (₹) | ₹2.48 | ₹2.79 | ₹2.72 | ₹1.49 | ₹1.67 | ₹1.42 |
| Cash from operations | ₹3 Cr | ₹5 Cr | −₹4 Cr | −₹1 Cr | −₹3 Cr | ₹10 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹4 Cr | ₹3 Cr | ₹2 Cr |
| Shareholders' equity | ₹92 Cr | ₹99 Cr | ₹114 Cr | ₹117 Cr | ₹133 Cr | ₹138 Cr |
Aarey Drugs & Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.80% | 44.80% | 44.80% | 39.06% | 37.71% | 37.71% |
| Foreign institutions | 2.34% | 1.97% | 1.13% | 3.86% | 4.18% | 4.80% |
| Domestic institutions | — | — | — | — | 1.62% | 1.62% |
| Non-institutions | 52.86% | 53.23% | 54.07% | 57.09% | 56.49% | 55.86% |
Aarey Drugs & Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Aarey Drugs & Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDICAMEQMedicamen Biotech | ₹266.50 | −0.11% | −14.0% | ₹361 Cr | 36.9 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| NURECANureca | ₹338.50 | +2.92% | +44.4% | ₹323 Cr | 159.7 | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹111.75 | −0.84% | +31.2% | ₹317 Cr | 80.4 | — |
| LYKALABSLyka Labs | ₹82.64 | −1.99% | −13.2% | ₹299 Cr | — | — |
| BIJHANSBijoy Hans | — | — | — | ₹292 Cr | — | — |
| ASTONEALABAstonea Labs | — | — | — | ₹281 Cr | — | — |
Ask anything about Aarey Drugs & Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against AAREYDRUGS's own history. Try: “Why has AAREYDRUGS moved over the last three months?” · “Backtest a 50-day moving-average crossover on AAREYDRUGS over five years” · “Compare AAREYDRUGS with MEDICAMEQ on margins and valuation”
Frequently asked questions about Aarey Drugs & Pharmaceuticals
What is the share price of Aarey Drugs & Pharmaceuticals today?
Aarey Drugs & Pharmaceuticals (NSE: AAREYDRUGS) last closed at ₹111.75 on 22 Oct 2026. Its 52-week high is ₹114.80 and its 52-week low is ₹50.31.
What is the market cap of Aarey Drugs & Pharmaceuticals?
Aarey Drugs & Pharmaceuticals' market capitalisation is ₹317 Cr (₹317 Cr) at the 22 Oct 2026 close, ranking 2018th among the NSE companies Pivot tracks.
What is the P/E ratio of Aarey Drugs & Pharmaceuticals?
Aarey Drugs & Pharmaceuticals trades at a trailing P/E of 80.4.
What is the ROE and ROCE of Aarey Drugs & Pharmaceuticals?
Return on equity was 2.9% in FY25 and return on capital employed was 7.6% in FY25 (standalone figures).
Is Aarey Drugs & Pharmaceuticals a debt-free company?
No. Aarey Drugs & Pharmaceuticals' debt-to-equity ratio was 0.25 in FY25, with total debt of ₹2 Cr.
What were Aarey Drugs & Pharmaceuticals' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Aarey Drugs & Pharmaceuticals reported revenue of ₹189 Cr, +75.3% year on year, and net profit of ₹2 Cr, +231.9% year on year.
How has Aarey Drugs & Pharmaceuticals stock performed over the last year?
Aarey Drugs & Pharmaceuticals' share price has risen 31.2% over the past year, +47.1% over three months and +11.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Aarey Drugs & Pharmaceuticals?
As of 30 Jun 2026: promoters 37.71%, foreign institutions 4.80%, domestic institutions 1.62%, non-institutions 55.86%.
Who are Aarey Drugs & Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Aarey Drugs & Pharmaceuticals by market cap are Medicamen Biotech, Astal Lab, Nureca, Lyka Labs, Bijoy Hans and Astonea Labs.
Is Aarey Drugs & Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aarey Drugs & Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AAREYDRUGS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text